Why Sagimet Biosciences Stock Is Soaring Today [Yahoo! Finance]
Sagimet Biosciences Inc. (SGMT)
Company Research
Source: Yahoo! Finance
Nevertheless, seeing the official announcement has clearly proven inspiring. As of 11:40 a.m. ET Monday, SGMT shares are up a hefty 45.2%, reaching a high last seen in November. The news? Following a successful Phase 3 trial in China, the biopharma company now plans to initiate Phase 3 trials of its acne-fighting denifanstat in the United States. Will AI create the world's first trillionaire? Our team just released a report on a little-known company, called an "Indispensable Monopoly," providing the critical technology Nvidia and Intel both need. Continue » Moving ahead to enter the U.S. acne market It's not the only drug in Sagimet's pipeline, for the record. Its TVB-3567 is also in Phase 1 trials as an acne treatment, as well as currently in preclinical studies as a treatment for solid tumors. Denifanstat also recently ended Phase 1 testing as a combo therapy for metabolic dysfunction associated steatohepatitis (MASH), with Phase 2 trials for this purpose expected to be re
Show less
Read more
Impact Snapshot
Event Time:
SGMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMT alerts
High impacting Sagimet Biosciences Inc. news events
Weekly update
A roundup of the hottest topics
SGMT
News
- Sagimet Biosciences (SGMT) had its price target lowered by Guggenheim from $27.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- Sagimet Biosciences Shares Jump 30% on Acne Trial Expansion Plans [Yahoo! Finance]Yahoo! Finance
- Why Sagimet Biosciences Stock Is Soaring Today [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common StockGlobeNewswire
- Sagimet Biosciences Provides Strategic and Corporate Updates [Yahoo! Finance]Yahoo! Finance
SGMT
Earnings
- 3/11/26 - Beat
SGMT
Sec Filings
- 4/28/26 - Form 8-K
- 4/28/26 - Form 424B5
- 4/27/26 - Form 8-K
- SGMT's page on the SEC website